News Releases

Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study

With incorporation of key learnings, Phase 2b has >95% (approaching 100%) statistical power  to meet its primary endpoint: change in Clinical Dementia Rating Sum-of-Boxes (CDR-SB) vs. placebo  New data included in the presentation show that in patients without Alzheimer's-related co-pathology,

Final publication in Neurology® of Phase 2a Results Stratified by Plasma Phosphorylated Tau Status at Baseline Strengthens the Case for Progressing Neflamapimod as a Disease-Modifying Treatment for Dementia with Lewy Bodies Research Highlight Article in Molecular Neurodegeneration Comments That

Oral neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health and slow or prevent disease progression, which would make it the first disease-modifying treatment in DLB Phase 2b RewinD-LB study underway; completion of enrollment planned in 1H 2024, and topline primary

BOSTON , Oct. 5, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced it will participate in the 2023 Roth Healthcare Opportunities Conference on Thursday, October 12, 2023 in New York .

Additional protocol-specified analyses of the AscenD-LB Phase 2a results show that patients without elevated plasma ptau181 levels are more responsive than those with such elevation and have substantial treatment benefits to neflamapimod.

BOSTON , Sept. 5, 2023 /PRNewswire/ --  CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced that the Company's senior management team will present at the H.C. Wainwright 25th Annual Global Investment

Shares of CervoMed to commence trading on Nasdaq under new ticker symbol "CRVO" on August 17, 2023 CervoMed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with Lewy bodies and other degenerative diseases of the brain CervoMed has a cash runway

BOSTON, Aug. 14, 2023 /PRNewswire/  --   EIP Pharma Inc.  ("EIP Pharma" or the "Company"), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, today announced that the first patient has been dosed in the Company's RewinD-LB Phase 2b clinical

BOSTON, Aug. 3, 2023 /PRNewswire/ --  EIP Pharma Inc. , a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company's senior management team will present at the Canaccord Genuity 43 rd  Annual Growth Conference on Wednesday, August